World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Case Report

Volume 6, Number 4, August 2015, pages 426-428


Posterior Reversible Encephalopathy Syndrome in a Bone Marrow Transplant Patient: A Complication of Immunosuppressive Drugs?

Table

Table 1. Conditions at Risk for PRES [7-12]
 
Hypertensive encephalopathy
Acute or chronic renal disease
Toxemia of pregnancy
Post-transplantation
  Allo-BMT
  Solid organ transplantation
Infection/sepsis/shock
  Multiorgan dysfunction syndrome
Autoimmune disease
  Systemic lupus erythematosus
  Wegener’s granulomatosis
  Polyarteritis nodosa
  Cryoglobulinemia
Immunosuppressive, immunomodulatory, and chemotherapeutic drugs
  Bevacizumab
  Cisplatin and other platinum based agents
  Cyclosporin
  Tacrolimus
  Cytarabine
  Gemcitabine
  Interferon-alpha
  Intravenous immunoglobulin
  Ipilimumab
  Methotrexate
  Rituximab
  Tyrosine kinase inhibitors (pazopanib), sorafenib, sunitinib
  Vincristine
Thrombotic thrombocytopenic purpura
Hemolytic and uremic syndrome
Miscellaneous reported associations
  Hypomagnesemia [8, 9]
  Hypercalcemia [10, 11]
  Hypocholesterolemia [12]
  Ephedra overdose
  Triple-H Therapy
  Tumor lysis syndrome
  Dialysis/erythropoietin syndrome
Porphyria
Contrast media exposure (cerebral, coronary angiography)